Desmopressin Trial for Cushing Syndrome Test Now Recruiting

On August 10, 2026, a clinical trial involving desmopressin was listed as recruiting. The study, registered as NCT06635629, is titled "Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome." It is a Phase 2 trial. According to the listing, the trial's current status is recruiting, meaning it is actively enrolling participants as of the date reported. The trial focuses on evaluating how the desmopressin stimulation test performs in the context of ACTH-dependent Cushing syndrome. No results have been posted for this trial at this time, and the event data does not include information on outcomes, efficacy, or safety findings. The listing reflects only the trial's registration status and phase classification. Desmopressin is an approved compound, and this trial update pertains specifically to its use in a diagnostic testing context for Cushing syndrome. Further details on the trial, including eligibility criteria and study design, are available through the official clinical trial registry listing. Readers interested in general background on desmopressin can consult the compound overview for additional context.